Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 0.50 |
| ▸ | MCHR2 | Q969V1 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539021 | 0.92 | EGFR (0.46) | MCHR1MCHR2CYP3A4CYP2C19HTR7 | |
| SCHEMBL29804080 | 0.89 | EGFR (0.56) | MCHR1MCHR2EGFR | |
| SCHEMBL110445 | 0.89 | EGFR (0.56) | MCHR1MCHR2EGFR | |
| SCHEMBL17678223 | 0.88 | KMO (0.58) | MCHR1MCHR2HTR7EGFR | |
| SCHEMBL17678308 | 0.82 | EGFR (0.58) | MCHR1EGFR | |
| SCHEMBL538977 | 0.82 | MCHR1 (0.53) | MCHR1MCHR2CYP3A4CYP2C19KCNH2 | |
| SCHEMBL18731915 | 0.82 | MCHR1 (0.61) | MCHR1MCHR2CYP3A4CYP2C19KCNH2 | |
| SCHEMBL384710 | 0.82 | MCHR1 (0.50) | MCHR1MCHR2CYP3A4CYP2C19KCNH2 | |
| SCHEMBL23533660 | 0.81 | HTR7 (0.42) | MCHR1MCHR2CYP3A4CYP2C19HTR7 | |
| SCHEMBL23533661 | 0.81 | HTR7 (0.42) | MCHR1MCHR2CYP3A4CYP2C19HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618132-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-12-31 | — | — | US | disclosed |
| EP-1558578-B1 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-03-13 | — | — | EP | disclosed |
| CN-101687879-B | 5-furopyridinone substituted indazoles | ALBANY MOLECULAR RES INC | 2013-01-02 | — | — | CN | disclosed |
| US-8273770-B2 | 5-pyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273770-B2 | 5-pyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273770-B2 | 5-pyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8268868-B2 | 5-pyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268868-B2 | 5-pyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268868-B2 | 5-pyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2176251-B1 | 5-pyridinone substituted indazoles and pharmaceutical compositions thereof | ALBANY MOLECULAR RES INC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20090082359-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | AMR TECHNOLOGY, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082359-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | AMR TECHNOLOGY, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-03-12 | — | — | US | disclosed |
| WO-2009015037-A2 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-7452911-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-11-18 | — | — | US | disclosed |
| WO-2008086409-A1 | 5-FUROPYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086409-A1 | 5-FUROPYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086404-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086404-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20040209865-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | MCHR1 1/4885MCHR2 2/4885CYP3A4 3399/4885 |
| US-20040209865-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MCHR2, NPY1R | MCHR1 1/4885MCHR2 2/4885CYP3A4 3279/4885 |
| US-20090082359-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | CYP3A5, PNPO, NDUFS3 | MCHR1 4349/4885MCHR2 4437/4885CYP3A4 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.